Research article
Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials
1 Pain Research, Nuffield Division of Anaesthetics, Nuffield Department of Clinical Neuroscience, University of Oxford, The Churchill, Oxford, OX3 7LE, UK
2 Medical Affairs, Primary Care Unit, Pfizer Inc, 235 E 42nd Street, New York, NY 10017, USA
3 Statistics, Primary Care Unit, Pfizer Inc, 235 E 42nd Street, New York, NY 10017, USA
Arthritis Research & Therapy 2013, 15:R6 doi:10.1186/ar4134
Published: 8 January 2013Additional files
Additional file 1:
Clinical studies included in the pooled analysis. A list containing the clinical studies included in the pooled analysis and the duration of treatment and treatment groups of each clinical study.
Format: DOCX Size: 19KB Download file
Additional file 2:
Kaplan-Meier plot of time to incidence of CSULGIEs or symptomatic ulcers. The time to incidence of CSULGIEs was significantly longer with celecoxib than with nsNSAIDs. CSULGIEs, clinically significant upper and lower GI events; nsNSAID, nonselective nonsteroidal antiinflammatory drug.
Format: TIFF Size: 367KB Download file
Additional file 3:
Kaplan-Meier plot of time to incidence of CSULGIEs, symptomatic ulcers, or hemoglobin decrease ≥ 2 g/dl of GI-related or potential GI cause. The time to incidence of CSULGIEs was significantly longer with celecoxib than with nsNSAIDs. CSULGIEs, clinically significant upper- and lower-GI events; GI, gastrointestinal; nsNSAID, nonselective nonsteroidal antiinflammatory drug.
Format: TIFF Size: 403KB Download file
